Clinical trials: Skin Diseases
IL-2 Induced Hypotension
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
The clinical use of IL-2 is currently limited by development of dose-dependent hypotension (systolic blood pressure (SBP) < 90 mm Hg).
- Trial name
- NCT00033956
- Testing
- M40403
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- MetaPhore Pharmaceuticals
Onychomycosis
Pilot Study to Evaluate Plasma Treatment of Onychomycosis
The purpose of this study is to evaluate the safety of treating human toenails with atmospheric plasma (MOE Antimicrobial Plasma Treatment System) and get an initial evaluation of the efficacy of this treatment for toenail fungus…
- Trial name
- NCT01819051
- Testing
- MOE Antimicrobial Plasma Treatment System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Moe Medical Devices
Rheumatoid Arthritis
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis.
- Trial name
- NCT00661661
- Testing
- CP-690,550
- Where
- 56 sites in Japan
- Volunteers
- 487 people
- Sponsor
- Pfizer
Keratosis, Actinic
UV Sensor in Patients With Actinic Keratosis
To validate the use of Ultraviolet (UV) radiation sensor in patients with actinic keratosis, to identify barriers to its use in prospective longitudinal studies.
- Trial name
- NCT05481073
- Testing
- UV sensor
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Almirall, S.A.
Hypertrophic Scar, Keloid Scar
A Substantial Equivalence Study of RD04723 and Predicate Device
The purpose of this study is to determine whether a developmental formulation is substantially equivalent to the predicate device in the treatment of hypertrophic and keloid scars.
- Trial name
- NCT01736969
- Testing
- RD047-023, Predicate Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oculus Innovative Sciences, Inc.
Breast Neoplasms, Breast Diseases
Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer
The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H\&E) and…
- Trial name
- NCT01136369
- Testing
- OSNA Breast Cancer System
- Where
- 11 sites in United States
- Volunteers
- 496 people
- Sponsor
- Sysmex America, Inc.
Rheumatoid Arthritis
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
This open-label, multi-center, two-arm, uncontrolled and non-randomized study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01332994
- Testing
- rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra]
- Where
- 83 sites in Germany
- Volunteers
- 519 people
- Sponsor
- Hoffmann-La Roche
Sanfilippo Syndrome B
Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome
This is an open-label, phase I/II study of intra-cerebral administration of adenovirus-associated viral vector containing the human NAGLU cDNA to children suffering from Sanfilippo type B syndrome.
- Trial name
- NCT03300453
- Testing
- rAAV2/5-hNAGLU
- Where
- France
- Volunteers
- 4 people
- Sponsor
- UniQure Biopharma B.V.
Diabetes, Foot Ulcer
Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer
It is estimated that 300 million people worldwide will have diabetes by the year 2025. About 12 percent of those with diabetes will have had a foot ulcer, which is a major source of morbidity, concern, and cost.
- Trial name
- DERMAGEN® (NCT00521937)
- Testing
- Dermagen®
- Where
- 7 sites in France
- Volunteers
- 388 people
- Sponsor
- Laboratoires Genévrier
Mucopolysaccharidosis VI
A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
Mucopolysaccharidoses (MPS) are a group of rare inherited disorders characterized by a deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs).
- Trial name
- iMProveS (NCT03370653)
- Testing
- Odiparcil
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 20 people
- Sponsor
- Inventiva Pharma
Acne Vulgaris
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
This study is being conducted to obtain safety, efficacy, and satisfaction data on the combination of topical Benzoyl Peroxide (BPO) 2.5% and the topical keratolytic agent Salicylic Acid (SA) 0.5% in the treatment of moderate to…
- Trial name
- NCT01446237
- Testing
- acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
- Where
- 9 sites in United States
- Volunteers
- 125 people
- Sponsor
- Stiefel, a GSK Company
Pressure Ulcer
Comparative Prevention-effectiveness Trial of DabirAIR Overlay System
Henry Ford Health System will evaluate the DabirAIR overlay system (DOS) for its effectiveness in preventing hospital acquired pressure ulcer (HAPU) in the peri-operative setting.
- Trial name
- NCT02565797
- Testing
- DabirAIR alternating pressure overlay
- Where
- United States
- Volunteers
- 392 people
- Sponsor
- Dabir Surfaces Inc
Radiodermatitis; Acute
A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer
This clinical trial is testing a new skin gel called GR1014-CG to evaluate its safety and see if it can help prevent or reduce skin irritation (such as redness, soreness, etc.) caused by radiation therapy (RT) after…
- Trial name
- GuARD (NCT07192588)
- Testing
- GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 273 people
- Sponsor
- Graegis Pharmaceuticals Ltd
Bone Neoplasms
Bonefos and the Consumption of Analgesics
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
- Trial name
- BICAM (NCT00909142)
- Testing
- Bonefos (Clodronate, BAY94-8393)
- Where
- Czechia
- Volunteers
- 149 people
- Sponsor
- Bayer
Chronic Spontaneous Urticaria
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
- Trial name
- CALM-CSU (NCT06077773)
- Testing
- Oral EP262
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 113 people
- Sponsor
- Escient Pharmaceuticals, Inc
Healthy Volunteers, Psoriasis
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male subjects (Part 1) and in patients with psoriasis (Part 2).
- Trial name
- NCT03493269
- Testing
- BAY1834845, Midazolam
- Where
- 2 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Acne
Safety and Efficacy of Skincare Products for Managing Mild to Moderate Acne in Individuals With Sensitive Skin
To investigate the safety and efficacy of a skincare regimen in individuals with mild to moderate acne and sensitive skin. The study duration is 4 weeks and the skin assessment will be carried out at baseline and week 4.
- Trial name
- NCT07749469
- Testing
- Cleanser, Toner, Serum
- Where
- Malaysia
- Volunteers
- 34 people
- Sponsor
- USMARI Research & Innovation Centre
Hypogonadism
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety…
- Trial name
- NCT00857454
- Testing
- Testosterone MD-Lotion
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Rosacea
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
- Trial name
- NCT03590366
- Testing
- B244, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- AOBiome LLC
Acne Vulgaris
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
- Trial name
- NCT03664739
- Testing
- IDP-120 Gel, IDp-120 Vehicle Gel
- Where
- 30 sites in United States, Canada
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.